The Circassia Effect: Why Specialty Pharma Companies Are Lining Up To List In London
This article was originally published in Scrip
Executive Summary
With debate ongoing as to whether biotech stocks are in a 'bubble' that could burst imminently, or if bullish valuations of early stage assets are completely justified, two companies are gambling on the positive investment climate in the UK by announcing plans for initial public offerings (IPOs) on the London Stock Exchange.